To investigate the extent to which Ang II/AT1R signaling activation impacts the development of non-alcoholic fatty liver, we administered the AT1R antagonist, losartan, using the same protocol as above for PRO20. This evidence concerns the gene AGTR1 and digestive system neoplasm.